COCP
NASDAQ
US
Cocrystal Pharma, Inc. - Common Stock
$1.51
▲ +$0.49
(+48.04%)
Vol 136.5M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$13.5M
ROE
-129.7%
Margin
-480.1%
D/E
0.00
Beta
1.23
52W
$1–$3
Wall Street Consensus
8 analysts · Apr 20262
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 100.0%
Next Report
May 13, 2026
EPS Estimate: $-0.14
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.14 | — | — |
| Dec 2025 | $-0.18 | $-0.17 | +$0.01 |
| Sep 2025 | $-0.21 | $-0.19 | +$0.02 |
| Jun 2025 | $-0.31 | $-0.20 | +$0.11 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$4.9M | -$3.3M | -$2.3M | -$2.1M | -$2.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -142.9% | -136.2% | -142.9% | -142.9% | -129.7% | -129.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -480.1% | -480.1% | -480.1% | -480.1% | -480.1% |
| Gross Margin | — | 41.2% | 41.2% | 41.2% | 41.2% | 41.2% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.69 | 4.57 | 3.69 | 3.69 | 5.78 | 5.78 |
Key Ratios
ROA (TTM)
-89.8%
P/S (TTM)
6.71
P/B
2.2
EPS (TTM)
$-0.94
CF/Share
$-1.95
52W High
$3.26
52W Low
$0.90
$0.90
52-Week Range
$3.26
Financial Health
Free Cash Flow
-$1.4M
Net Debt
-$6.1M
Cash
$7.7M
Total Debt
$1.6M
As of Sep 30, 2025
How does COCP compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
COCP valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
6.7
▲
36%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
2.2
▲
2%
above
peers
(2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
COCP profitability vs Pharmaceuticals peers
ROE
-129.7%
▼
139%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-480.1%
▼
914%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
41.2%
▼
40%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-89.8%
▼
140%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
COCP financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
5.8
▲
72%
above
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
1.2
▲
31%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
COCP fundamentals radar
COCP
Peer median
Industry
COCP profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
COCP vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
FROST PHILLIP MD ET AL
Director and Beneficial Owner… · Feb 24
20000 shs
FROST PHILLIP MD ET AL
Beneficial Owner of more than… · Feb 06
50000 shs
Last 90 days
Top Holders
Top 5: 4.35%Vanguard Group Inc
1.92%
$272K
Renaissance Technologies, L…
0.91%
$130K
Geode Capital Management, L…
0.60%
$85K
Blackrock Inc.
0.54%
$76K
T3 Companies, LLC
0.38%
$54K
As of Dec 31, 2025
Latest News
No related news yet